Table 2.
Prostate-cancer-related characteristics according to glycaemic group
| Characteristics | Follow-up: 2002–2012 n = 1,034,074 |
Follow-up: 2005–2012 n = 997,440 |
||||
|---|---|---|---|---|---|---|
| Diabetes-free n = 765,483 |
Prevalent diabetes n = 74,756 |
Incident diabetes n = 193,835 |
Diabetes-free n = 746,551 |
Prevalent diabetes n = 65,001 |
Incident diabetes n = 185,888 |
|
| Person-years | 9,002,033 | 640,388 | 982,263 | 6,268,686 | 431,200 | 876,460 |
| Prostate cancer frequency, n (crude rate per annum × 103) | 9,714 (1.08) | 1,672 (2.61) | 2,713 (2.76) | 6,939 (1.11) | 1,113 (2.58) | 2,283 (2.60) |
| Gleason score for prostate cancer; n (%) | ||||||
| 2, 3, 4 (1a) | 177 (1.8) | 33 (2.0) | 31 (1.1) | 81 (1.2) | 14 (1.3) | 15 (0.7) |
| 5, 6 (2a) | 5,983 (61.6) | 852 (51.0) | 1,567 (57.8) | 4,666 (67.2) | 623 (56.0) | 1,375 (60.2) |
| 7–10 (3a) | 1,742 (17.9) | 358 (21.4) | 623 (23.0) | 1,319 (19.0) | 269 (24.2) | 539 (23.6) |
| Unknown | 1,812 (18.7) | 429 (25.6) | 492 (18.1) | 873 (12.6) | 207 (18.6) | 354 (15.5) |
| PSA screening in 2002–2003 | ||||||
| No PSA screening | 677,412 (90.7) | 47,025 (72.4) | 144,003 (77.5) | |||
| PSA screen in 1 out of 2 years | 50,505 (6.8) | 12,990 (20.0) | 29,671 (16.0) | |||
| PSA screen in 2 out of 2 years | 18,634 (2.5) | 4,986 (7.7) | 12,214 (6.6) | |||
a1, 2, 3: According to Middle East Cancer Consortium manual of coding and staging [27]